Plain-English translation of NCT06728852 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called Vorolanib for people with advanced non-small cell lung cancer (a common type of lung cancer) whose disease has continued to progress despite receiving at least two prior treatments. Vorolanib works by blocking the growth of new blood vessels that tumors need to survive. The study will enroll 32 patients and measure whether this medication can slow cancer growth and how well patients tolerate it.
Many people with advanced lung cancer run out of effective treatment options after their cancer stops responding to standard chemotherapy and other targeted drugs. This trial exists to find out whether this medication could offer another option for patients in this difficult situation, potentially giving them more time and better quality of life.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take the medication as a daily oral dose at home. You will continue treatment until your cancer progresses, you experience side effects you cannot tolerate, or you decide to withdraw. Throughout the study, you will have regular clinic visits to monitor how well the medication is working, check your blood counts and organ function, and watch for any side effects. The study will track how long your cancer stays stable and measure your overall survival.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China